arginine supplementation effect on CVDs.

Phase 2

Completed

• Conditions: Obesity.; Obesity, unspecified

• Registration Number: IRCT201501183236N6
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

both sexes; BMI higher than than 29.9 kg/m2 or visceral obesity (BMI whithin25- 29.9 kg/m2 and wc more than 102 cm in men or more than 88 in women); acute or chronic inflammation; stable body weight 3 months before the start of the study (based on self report) absence of any current diet or supplement treatment; absence of antidiabetic, antihypertensive, antihyperlipidemic treatment; no history of ischemic heart disease; and normal renal and liver function. Exclusion criteria: Unwillingness to continue; the use of tobacco or alcohol during the study; taking any supplements other than the selected intervention; any disease or physiological changes that requires special treatment; failure to follow the intervention designing (not consuming dedicated supplement to the total amount less than 90% predicted or more than 3 days).

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified